Nuformix (LSE:NFX) Short-Term Debt : £0.00 Mil (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Short-Term Debt?

Nuformix's Short-Term Debt for the quarter that ended in Sep. 2022 was £0.00 Mil.

Nuformix's annual Short-Term Debt declined from Mar. 2020 (£0.01 Mil) to Mar. 2021 (£0.00 Mil) but then stayed the same from Mar. 2021 (£0.00 Mil) to Mar. 2022 (£0.00 Mil).

Nuformix Short-Term Debt Historical Data

The historical data trend for Nuformix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Short-Term Debt Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Short-Term Debt

Get a 7-Day Free Trial

0.02

0.01

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Short-Term Debt	Get a 7-Day Free Trial									-	-	-	-	-

Nuformix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Nuformix Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Nuformix's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuformix (LSE:NFX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.